located in Pilar, accompanied by Marcelo Figueiras, head of Laboratorios Richmond
Within the framework of our five-year US$ 80 million investment plan, one of the ongoing projects is the new 1500 m2 plant for the manufacture of high potency oral solid products, indicated for the treatment of oncology and multiple sclerosis, which will allow to produce state-of-the-art products in Argentina, contributing to the access to new treatments and import substitution.
“This investment is a sign of confidence and commitment to the country. We are convinced that we must all make the effort and we are excited to have the support of the President and his entire team, to ensure the accessibility of patients to quality treatments and create new sources of employment,” said Marcelo Figueiras.
Since the beginning of the pandemic, at Laboratorios Richmond we have continued to guarantee the normal and uninterrupted supply of our products and to carry out different initiatives that reaffirm our support for science, technology and industry, engines of the country’s development.